伊布替尼联合苯达莫司汀和利妥昔单抗治疗复发慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的3期HELIOS研究更新结果
报告随机、安慰剂对照3期HELIOS试验的随访结果,578例既往治疗过、无17p缺失的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者按1:1随机接受伊布替尼(420 mg每日)或安慰剂联合6周期苯达莫司汀和利妥昔单抗(BR),随后伊布替尼或安慰剂单药治疗。中位随访34.8个月,伊布替尼+BR组研究者评估的中位无进展生存期未达到,安慰剂+BR组为14.3个月(HR 0.206,95%CI 0.159-0.265;P<0.0001);36个月无进展生存率分别为68.0%和13.9%。两组中位总生存期均未达到,伊布替尼+BR对比安慰剂的HR为0.652(95%CI 0.454-0.935;P=0.019)。
要点
- 伊布替尼+BR组研究者评估的中位无进展生存期未达到,安慰剂+BR组为14.3个月(HR 0.206,95%CI 0.159-0.265;P<0.0001)。
- 36个月无进展生存率伊布替尼+BR组为68.0%,安慰剂+BR组为13.9%。
- 微小残留病灶阴性缓解率伊布替尼+BR组为26.3%,安慰剂+BR组为6.2%(P<0.0001)。
核心结论
- 这些长期数据支持伊布替尼+BR相比BR在复发慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中改善生存结局并加深缓解。
研究设计与样本
- 随机、安慰剂对照3期HELIOS试验,纳入既往治疗过、无17p缺失的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者578例,按1:1随机接受伊布替尼(420 mg每日)或安慰剂联合6周期苯达莫司汀和利妥昔单抗(BR),随后伊布替尼或安慰剂单药治疗。
- 中位随访34.8个月(范围0.1-45.8个月)。
主要发现
- 研究者评估的中位无进展生存期伊布替尼+BR组未达到,安慰剂+BR组为14.3个月(HR 0.206,95%CI 0.159-0.265;P<0.0001)。
- 36个月无进展生存率伊布替尼+BR组为68.0%,安慰剂+BR组为13.9%。
- 结果与主要分析一致(独立审查委员会评估的HR=0.203,中位随访17个月)。
- 中位总生存期两组均未达到;伊布替尼+BR对比安慰剂的HR为0.652(95%CI 0.454-0.935;P=0.019)。
- 微小残留病灶阴性缓解率伊布替尼+BR组为26.3%,安慰剂+BR组为6.2%(P<0.0001)。
关键数值与推荐
- 治疗中出现的不良事件(包括3-4级)发生率与初始HELIOS报告基本一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Overall, 578 patients were randomized 1:1 to either ibrutinib (420 mg daily) or placebo, in combination with 6 cycles of BR, followed by ibrutinib or placebo alone. Median follow-up was 34.8 months (range: 0.1-45.8). Investigator-assessed median progression-free survival (PFS) was not reached for ibrutinib+BR, versus 14.3 months for placebo+BR (hazard ratio [HR] [95% CI], 0.206 [0.159-0.265]; P < 0.0001); 36-month PFS rates were 68.0% versus 13.9%, respectively. The results are consistent with the primary analysis findings (HR = 0.203, as assessed by independent review committee, with 17-month median follow-up). Median overall survival was not reached in either arm; HR (95% CI) for ibrutinib+BR versus placebo: 0.652 (0.454-0.935; P = 0.019). Minimal residual disease (MRD)-negative response rates were 26.3% for ibrutinib+BR and 6.2% for placebo+BR (P < 0.0001). Incidence of treatment-emergent adverse events (including grades 3-4) were generally consistent with the initial HELIOS report. These long-term data support improved survival outcomes and deepening responses with ibrutinib+BR compared with BR in relapsed CLL/SLL.
引用
- Fraser G, Cramer P, Demirkan F, et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia. 2018. PMID: 30315239. doi:10.1038/s41375-018-0276-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。